Evaluation of muscle glycogen content by 13C NMR spectroscopy in adult-onset acid maltase deficiency

Neuromuscular Disorders

Volumn 13, Issue 7-8, 2003, Pages 545-553

  Wary, Claire ^a   Laforêt, Pascal ^b   Eymard, Bruno ^b   Fardeau, Michel ^b   Leroy Willig, Anne ^a   Bassez, Guillaume ^c   Leroy, Jean Paul ^d   Caillaud, Catherine ^e   Poenaru, Livia ^e   Carlier, Pierre G ^a  

^a DIF   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d BREST UNIVERSITY HOSPITAL   (France)

^e Cochin University Hospital ^*  (France)

Author keywords

Alpha glucosidases; Glycogen storage disease type II; Magnetic resonance spectroscopy

Indexed keywords

CREATINE; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLYCOGEN;

ADOLESCENT; ADULT; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLYCOGEN METABOLISM; GLYCOGEN MUSCLE LEVEL; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; MALE; PRIORITY JOURNAL; REPRODUCIBILITY;

EID: 0041570135     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(03)00069-5     Document Type: Article

References (51)

1. Engel A.G., Hirschhorn R. Acid maltase deficiency. Engel A.G., Franzini-Armstrong C. Myology, basic and clinical. 2nd ed. 1994;1533-1552 McGraw-Hill, New York, NY. (chap. 58).
2. Hirschhorn R. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The metabolic and molecular bases of inherited disease. 7th ed. 1995;2443-2464 McGraw-Hill, New York, NY.
3. Engel A.G., Gomez M.R., Seybold M.E., Lambert E.H. The spectrum and diagnosis of acid maltase deficiency. Neurology. 23:1973;95-106.
4. Karpati G., Carpenter S., Eisen A., Aube M., DiMauro S. The adult form of acid maltase (alpha-1,4-glucosidase) deficiency. Ann Neurol. 1:1977;276-280.
5. Swash M., Schwartz M.S., Apps M.C. Adult onset acid maltase deficiency. Distribution and progression of clinical and pathological abnormality in a family. J Neurol Sci. 68:1985;61-74.
6. Stevens A.N., Iles R.A., Morris P.G., Griffiths J.R. Detection of glycogen in a glycogen storage disease by 13C nuclear magnetic resonance. FEBS Lett. 150:1982;489-493.
7. Beckmann N., Seelig J., Wick H. Analysis of glycogen storage disease by in vivo 13C NMR: comparison of normal volunteers with a patient. Magn Reson Med. 16:1990;150-160.
8. 13C NMR spectroscopy. Neuromuscul Disord. 1:1991;99-101.
9. 13C-NMR evaluation of glycogen content in a patient with glycogen storage disease. J Inherit Metab Dis. 15:1992;723-726.
10. Jehenson P., Duboc D., Labrune P., Fardeau M., Odievre M., Syrota A. Diagnostic value of the evaluation of the glycogen content in muscle diseases by carbon 13 nuclear magnetic resonance. J Chim Phys. 92:1995;1797-1800.
11. Roser W., Beckmann N., Wiesmann U., Seelig J. Absolute quantification of the hepatic glycogen content in a patient with glycogen storage disease by 13C magnetic resonance spectroscopy. Magn Reson Imaging. 14:1996;1217-1220.
12. Dreyfus J.C., Poenaru L. White blood cells and the diagnosis of alpha-glucosidase deficiency. Pediatr Res. 14:1980;342-344.
13. Kroos M.A., Van der Kraan M., Van Diggelen O.P., et al. Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients. J Med Genet. 32:1995;836-837.
14. Laforet P., Nicolino M., Eymard P.B., et al. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology. 55:2000;1122-1128.
15. Haase A., Frahm J., Matthaei D., Hanicke W., Merboldt K.D. FLASH imaging. Rapid NMR imaging using low flip-angle pulses. J Magn Reson. 67:1986;258-266.
16. Barkhuijsen H., de Beer R., van Ormondt D. Improved algorithm for noniterative time-domain model fitting to exponentially damped magnetic resonance signals. J Magn Reson. 73:1987;553-557.
17. Iwamasa T., Ninomiya N., Fukuda S., Hamada T., Hirashima M., Osame M. Glycogen storage disease. Studies related to mechanism of glycogenosome formation. Pathol Res Pract. 176:1983;236-252.
18. Trend P.S., Wiles C.M., Spencer G.T., Morgan-Hughes J.A., Lake B.D., Patrick A.D. Acid maltase deficiency in adults. Diagnosis and management in five cases. Brain. 108:1985;845-860.
19. Ausems M.G., Verbiest J., Hermans M.P., et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. 7:1999;713-716.
20. van den Bergh A.J., Houtman S., Heerschap A., et al. Muscle glycogen recovery after exercise during glucose and fructose intake monitored by 13C-NMR. J Appl Physiol. 81:1996;1495-1500.
21. Harris R.C., Hultman E., Nordesjo L.O. Glycogen, glycolytic intermediates and high-energy phosphates determined in biopsy samples of musculus quadriceps femoris of man at rest. Methods and variance of values. Scand J Clin Lab Invest. 33:1974;109-120.
22. Tarnopolsky M.A., Parise G. Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease. Muscle Nerve. 22:1999;1228-1233.
23. Keltner J.R., Carlson J.W., Roos M.S., Wong S.T., Wong T.L., Budinger T.F. Electromagnetic fields of surface coil in vivo NMR at high frequencies. Magn Reson Med. 22:1991;467-480.
24. Hoult D.I., Phil D. Sensitivity and power deposition in a high-field imaging experiment. J Magn Reson Imaging. 12:2000;46-67.
25. 31P NMR using surface coils. Nature. 283:1980;167-170.
26. de Graaf R.A., Nicolay K. Adiabatic rf pulses: applications to in vivo NMR. Concepts Magn Reson. 9:1997;247-268.
27. van Cauteren M., Miot F., Segebarth C.M., Eisendrath H., Osteaux M., Willem R. Excitation characteristics of adiabatic half-passage RF pulses used in surface coil MR spectroscopy. Application to 13C detection of glycogen in the rat liver. Phys Med Biol. 37:1992;1055-1064.
28. Hajduk P.J., Horita D.A., Lerner L.E. Theoretical analysis of relaxation during shaped pulses. I The effects of short T1 and T2. J Magn Reson. A:1993;40-52.
29. Murphy E., Hellerstein M. Is in vivo nuclear magnetic resonance spectroscopy currently a quantitative method for whole-body carbohydrate metabolism? Nutr Rev. 58:2000;304-314.
30. Geddes R., Stratton G.C. The influence of lysosomes on glycogen metabolism. Biochem J. 163:1977;193-200.
31. 1H in solution. Biochemistry. 32:1993;9417-9422.
32. 13C NMR relaxation times of hepatic glycogen in vitro and in vivo. Biochemistry. 29:1990;6815-6820.
33. Sillerud L.O., Shulman R.G. Structure and metabolism of mammalian liver glycogen monitored by carbon-13 nuclear magnetic resonance. Biochemistry. 22:1983;1087-1094.
34. 1H NMR visibility of mammalian glycogen in solution. Proc Natl Acad Sci USA. 87:1990;1678-1680.
35. Wary C., Desvaux H., Van Cauteren M., Vanstapel F., Carlier P.G., Jehenson P. 1H NMR spectroscopy study of the dynamic properties of glycogen in solution by steady-state magnetisation measurement with off-resonance irradiation. Carbohydr Res. 306:1998;479-491.
36. Geddes R., Jeyarathan P., Taylor J.A. Molecular and metabolic aspects of lysosomal glycogen. Carbohydr Res. 227:1992;339-349.
37. Calder P.C., Geddes R. Rat skeletal muscle lysosomes contain glycogen. Int J Biochem. 21:1989;561-567.
38. 13C NMR quantification of hepatic glycogen. NMR Biomed. 6:1993;371-376.
39. Gruetter R., Magnusson I., Rothman D.L., Avison M.J., Shulman R.G., Shulman G.I. Validation of 13C NMR measurements of liver glycogen in vivo. Magn Reson Med. 31:1994;583-588.
40. Gruetter R., Prolla T.A., Shulman R.G. 13C NMR visibility of rabbit muscle glycogen in vivo. Magn Reson Med. 20:1991;327-332.
41. 13C NMR measurement of human skeletal muscle glycogen by direct biochemical assay of needle biopsy samples. Magn Reson Med. 27:1992;13-20.
42. Griffin J.L. Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture. Virchows Arch B Cell Pathol Incl Mol Pathol. 45:1984;23-36.
43. Fujita T., Nonaka I., Sugita H. Japanese quail and human acid maltase deficiency: a comparative study. Brain Dev. 13:1991;247-255.
44. Howell J.M., Dorling P.R., Cook R.D. The effect of age on biochemical and morphological changes in the semitendinosus muscle of cattle with generalized glycogenosis type II. Neuropathol Appl Neurobiol. 10:1984;255-266.
45. Raben N., Nagaraju K., Lee E., Plotz P. Modulation of disease severity in mice with targeted disruption of the acid alpha-glucosidase gene. Neuromuscul Disord. 10:2000;283-291.
46. Amalfitano A., Bengur A.R., Morse R.P., et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med. 3:2001;132-138.
47. Chen Y.T., Amalfitano A. Towards a molecular therapy for glycogen storage disease type II (Pompe disease). Mol Med Today. 6:2000;245-251.
48. Van den Hout H., Reuser A.J., Vulto A.G., Loonen M.C., Cromme-Dijkhuis A., Van der Ploeg A.T. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 356:2000;397-398.
49. Bijvoet A.G., Van Hirtum H., Kroos M.A., et al. Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet. 8:1999;2145-2153.
50. Kikuchi T., Yang H.W., Pennybacker M., et al. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest. 101:1998;827-833.
51. Evelhoch J.L., Growley M.J., Ackerman J.J.H. Signal-to-noise optimization and observed volume localization with circular surface coils. J Magn Reson. 56:1984;110-124.